Navigation Links
Le cardio pourrait être la clé pour soigner le cancer
Date:4/25/2013

AMSTERDAM, April 26, 2013 /PRNewswire/ --

D'après une étude unique au monde réalisée sur des souris, la pratique d'un exercice régulier réduit le risque de développer un cancer du foie, apportant ainsi un espoir pour les patients à risque de carcinome hépatocellulaire (CHC).

     (Logo: http://photos.prnewswire.com/prnh/20120728/551976)

Les recherches présentées lors de l'International Liver Congress™ 2013 comprenaient deux groupes de souris soumises à un régime alimentaire contrôlé riche en matières grasses et ensuite divisées en deux catégories : les sédentaires et celles soumises à des exercices physiques. [1] Ces dernières ont couru sur un tapis roulant 60 minutes par jour, 5 jours par semaine.

Après 32 semaines d'exercice régulier, 71 % des souris sous régime alimentaire contrôlé ont développé une tumeur plus large de 10 mm contre 100 % des souris sédentarisées. Le nombre moyen et le volume des tumeurs CHC par foie a également été réduit dans le groupe de souris soumises aux exercices réguliers par rapport au groupe de souris sédentarisées.

Le Professeur Jean-François Dufour, Conseiller Pédagogique à l'EASL (European Association for the study of liver) a déclaré que les résultats démontraient le bénéfice considérable de pratiquer un exercice régulier sur la prévention du CHC. L'exercice réduit le niveau de stéatose hépatique non alcoolique chez les souris ayant reçu un régime riche en matières grasses. Il a ainsi affirmé : « Nous savons que les styles de vie actuels, malsains, prédisposent les populations à la stéatose hépatiqu
'/>"/>

SOURCE The European Association for the Study of the Liver (EASL)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
2. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
3. Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
4. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
5. CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
6. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
7. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
8. Interventional Cardiology Devices Market is Expected to Reach USD 25.2 Billion Globally in 2018: Transparency Market Research
9. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
10. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
11. Micropharma Convenes Expert Roundtable on New Role for Probiotics in Cardiovascular Disease in time for National Cholesterol Education Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2005 discovery of an enzyme that is a natural ... Diego (UCSD) School of Medicine have now identified two ... for therapies to treat diabetes, heart and neurological disease. ... professor of pharmacology, and colleagues are published in the ...
... years, orthopedic surgeon Dennis Crawford, M.D., Ph.D., of Oregon ... tissue for transplant to treat some of his patients ... this unfortunate and ironic," explained Crawford, assistant professor of ... and a specialist in sports medicine. "Oregonians, it turns ...
... cancer care was $2.3 billion in the first year after diagnosis, ... the Journal of the National Cancer Institute . The time ... cancer care varied widely, they write. , Several studies have ... attempted to include a patient's time associated with cancer care, such ...
Cached Biology News:UCSD researchers discover variants of natural tumor suppressor 2OHSU surgeon implants donated tissue allografts 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3
... Mouse monoclonal [PRMT5-21] to PRMT5 Arginine ... which has only recently been linked to ... PRMT enzymes have been identified in mammalian ... have essential regulatory functions by methylation of ...
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
Biology Products: